Shares of Genmab A/S (OTCMKTS:GNMSF – Get Free Report) hit a new 52-week high during trading on Saturday. The stock traded as high as $447.55 and last traded at $447.55, with a volume of 12,320 shares trading hands. The stock had previously closed at $388.5150.
Genmab A/S Stock Up 15.2%
The stock has a market capitalization of $27.56 billion, a P/E ratio of 27.81 and a beta of 0.75. The business has a 50-day simple moving average of $351.03 and a two-hundred day simple moving average of $299.08. The company has a quick ratio of 2.44, a current ratio of 2.46 and a debt-to-equity ratio of 0.81.
About Genmab A/S
Genmab A/S is a Denmark-based biotechnology company focused on discovering, developing and commercializing antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary technologies to create differentiated antibodies and antibody-drug conjugates designed to engage the immune system or target specific disease-related proteins.
Genmab’s technologies include the DuoBody platform for generating bispecific antibodies, as well as the HexaBody platform for developing antibodies with enhanced activity.
Recommended Stories
- Five stocks we like better than Genmab A/S
- Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs
- Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test
- Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers
- Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
